Schizophrenia
Schizophrenia - Related Videos
01:17
Schizophrenia
0 Views •
2025
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.
05:51
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
0 Views •
Cited by 11 •
2011
Molecular genetic strategy for finding de novo mutations causing common disorders such as autism and schizophrenia.
01:29
Psychological and Sociocultural Causes of Schizophrenia
0 Views •
2025
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
01:29
Biological Causes of Schizophrenia
0 Views •
2025
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood. Genetic Factors in Schizophrenia The genetic basis of schizophrenia is strongly supported by family and twin studies.
13:08
Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
0 Views •
Cited by 1 •
2015
This paper describes how to use the emotional oddball task and fMRI to measure brain activation in children and adolescents at familial high risk for schizophrenia (FHR). FMRI was used to measure differences in fronto-striato-limbic regions during an emotional oddball task. Children with FHR exhibited abnormal functional activation during adolescence.
FAQs
D2 receptors are central targets because reducing dopamine signaling through them can lessen psychosis in brain circuits associated with that symptom domain. This mechanism explains why many antipsychotic medicines are used to control psychotic symptoms. It also provides a pharmacological basis for comparing treatments according to their effects on dopamine pathways and observed clinical response.
Newer agents extend beyond D2 receptor effects by also influencing serotonin receptors. According to the overview, this broader receptor activity may help address a wider range of schizophrenia symptoms than dopamine-focused action alone. The distinction is important in pharmacology because receptor profiles provide one framework for understanding differences among medicines and their potential clinical effects.
Receptor mechanisms explain how a medicine may produce symptom control, but they do not determine an identical outcome for every patient. Treatment response varies widely, and adverse effects and adherence also differ. Consequently, pharmacological reasoning must connect a medicine’s mechanism with its observed benefits, tolerability, and continued use rather than relying on receptor action alone.
Antipsychotic medicines support immediate symptom control by targeting signaling mechanisms associated with psychosis, while continued treatment can contribute to relapse prevention. These goals are related but not interchangeable: a medicine may be selected not only for its effect on current symptoms, but also for its role in maintaining stability over time. Clinical pharmacology considers both outcomes.
Medication selection and monitoring should account for treatment response, adverse effects, and adherence because these factors vary widely among individuals. Pharmacological management therefore requires attention to how well symptoms are controlled, whether unwanted effects emerge, and whether the treatment can be followed consistently. These considerations help clinicians evaluate the practical value of a selected medicine.
Schizophrenia provides a setting for studying how receptor mechanisms translate into symptom control, broader clinical effects, and relapse prevention. Research must also explain why treatment response, adverse effects, and adherence vary across patients. This combination of biological targets and real-world treatment variability makes schizophrenia relevant to both medication development and the refinement of clinical pharmacology.